ir-(r4 [07

cc: Jkunz@annurev.org (Jean Kunz -Annual Reviews) AK
To: gubins@annurev.org (Sam Gubins-Annual Reviews) F
From: lederberg @mail.rockefeller.edu

Fcc: /jm/AR

Subject: Ann Rev Pathology; - Cancer Biology; Dec 13 ExCom

Dear Sam:

I respond somewhat belatedly to the work book for the recent ExCom.
I’m sorry this is so tardy, but I’ve had a very heavy travel schedule
this fall(Japan one trip; bangkok-Beijing another), and that’s wreaked
havoc with many good intentions.

It’s quite late in the day, but I have some misgivings about
AR-Path, mainly that a major competitor was not even mentioned.
There are frequent reviews (called Perspective, Clinical
Implications of Basic Research, Review Article, ...) in almost
every issue of the New England Journal. Less formidable are
"Mechanisms of Disease" in Lancet.

Maybe the guild doesn’t want to acknowledge all that as "pathology";
but judge for yourself the depth of overlap.

It might be a great convenience to have a annual collection of these articles
in book form.

There are contra’s to my remarks in the visibility of the proposed editors;
but I hope there is time to consult a bit more broadly.

ASIP sponsorship might count for a lot; but I’d also seek informed assurance
from an insider just what standing that society has.

I’m somewhat happier about AR Cancer Research; but there too is formidable
competition from Advances in Cancer Research. However, I know that the
NClI/director* and many workers in the field are eager to build cancer biology
as a bridging discipline, and there probably is room for another review

entry.

I know Andy von Eschenbach* pretty well, and he is quite dedicated to
better "translational" integration in Cancer Biology. I’d be willing to
pass on a case statement exploring the possibility of some subsidy from
NCI.